|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1990
|
|
gptkbp:atccode
|
L02 AE01
|
|
gptkbp:brand
|
gptkb:Zoladex
|
|
gptkbp:casnumber
|
120287-80-8
|
|
gptkbp:chemical_formula
|
C59 H84 N16 O14 S
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
hormone therapy
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to goserelin
|
|
gptkbp:dosage_form
|
depot injection
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:form
|
implant
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zoladex
|
|
gptkbp:ingredients
|
gptkb:goserelin
|
|
gptkbp:manufacturer
|
gptkb:Astra_Zeneca
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
Gn RH agonist
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:patient_population
|
adult men
adult women
children with precocious puberty
|
|
gptkbp:related_products
|
gptkb:Lupron
gptkb:Eligard
gptkb:Firmagon
gptkb:Trelstar
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:service_frequency
|
monthly
every 3 months
|
|
gptkbp:shelf_life
|
36 months
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
gastrointestinal disturbances
thromboembolic events
cardiovascular events
weight gain
injection site reactions
osteoporosis
mood changes
hot flashes
decreased libido
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
gptkb:Oncology
gptkb:endometriosis
precocious puberty
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca
|
|
gptkbp:bfsLayer
|
4
|